Cargando…

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy

Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) combined with chemotherapy in patients with RAS (rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer (mCRC) can alleviate and stabilize the disease, effectively prolong the progression-free surviv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Meiqin, Wang, Zeng, Lv, Wangxia, Pan, Hongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Molecular Biosciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006990/ https://www.ncbi.nlm.nih.gov/pubmed/35433839 http://dx.doi.org/10.3389/fmolb.2022.870395

Ejemplares similares

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial
por: Marmorino, Federica, et al.
Publicado: (2019)

mCRC: rasante Weiterentwicklung zielgerichteter Therapien
por: Arnheim, Katharina
Publicado: (2022)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
por: Schulz, Martin S., et al.
Publicado: (2022)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
por: Alig, Annabel H. S., et al.
Publicado: (2022)

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
por: Saif, Muhammad Wasif
Publicado: (2013)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview
por: Martín-Richard, Marta, et al.
Publicado: (2021)

Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment
por: Chen, Hong-Hwa, et al.
Publicado: (2021)

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib
por: Pommier, A J C, et al.
Publicado: (2014)

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
por: Rossi, Luigi, et al.
Publicado: (2013)

The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients
por: Yu, Ping, et al.
Publicado: (2018)

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies
por: Patel, Gargi S, et al.
Publicado: (2015)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

Targeting heparan sulfate-protein interactions with oligosaccharides and monoclonal antibodies
por: Li, Miaomiao, et al.
Publicado: (2023)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
por: Huemer, Florian, et al.
Publicado: (2018)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
por: Zhang, Yiyi, et al.
Publicado: (2021)

Production and characterization of monoclonal antibodies for the detection of the hepatitis C core antigen
por: Vidal-Alcántara, Erick Joan, et al.
Publicado: (2023)

Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC)
por: Tysarowski, Andrzej, et al.
Publicado: (2018)

Maximising clinical benefit with adequate patient management beyond the second line in mCRC
por: Argiles, Guillem, et al.
Publicado: (2019)

Monolithic Papain-Immobilized Enzyme Reactors for Automated Structural Characterization of Monoclonal Antibodies
por: Rinaldi, Francesca, et al.
Publicado: (2021)

Immuno-dominant dengue NS1 peptides as antigens for production of monoclonal antibodies
por: Munasinghe, Erandi, et al.
Publicado: (2022)

Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8(+) T Cells in Chinese Advanced Non–Small-Cell Lung Cancer Patients Treated With the Anti–PD-L1 Antibody
por: Sheng, Jin, et al.
Publicado: (2021)

Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
por: Bahl, Ankur, et al.
Publicado: (2020)

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Characterization and Value Assignment of a Monoclonal Antibody Reference Material, NMIJ RM 6208a, AIST-MAB
por: Kinumi, Tomoya, et al.
Publicado: (2022)

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
por: Kombe Kombe, Arnaud John, et al.
Publicado: (2021)

A Review of Methodologies for the Detection, Quantitation, and Localization of Free Cysteine in Recombinant Proteins: A Focus on Therapeutic Monoclonal Antibodies
por: Metcalfe, Clive
Publicado: (2022)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
por: Borelli, Beatrice, et al.
Publicado: (2022)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
por: Scarabel, Lucia, et al.
Publicado: (2022)

Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial
por: Ferreira, Cláudia S., et al.
Publicado: (2023)

Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2
por: Bae, Kieun, et al.
Publicado: (2022)

Uncovering the Mechanism of Drug Resistance Caused by the T790M Mutation in EGFR Kinase From Absolute Binding Free Energy Calculations
por: Zhou, Huaxin, et al.
Publicado: (2022)

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
por: Feliu, J, et al.
Publicado: (2014)

Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy
por: Quirino, Michela, et al.
Publicado: (2017)

Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development
por: Gmeiner, William H
Publicado: (2021)

KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research
por: He, Kang, et al.
Publicado: (2020)

Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab
por: Belviso, Benny Danilo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4h0uovkjivjn99nkrcjkllb3ul